Advice
following an abbreviated submission:
calcipotriol and betamethasone cutaneous foam (Enstilar®) is accepted for use within NHS Scotland.
Indication under review: topical treatment of psoriasis vulgaris in adults.
Enstilar® cutaneous foam is another licensed formulation of calcipotriol / betamethasone and may be associated with a small budget impact.
Download detailed advice50KB (PDF)
Medicine details
- Medicine name:
- calcipotriol + betamethasone (Enstilar)
- SMC ID:
- 1182/16
- Indication:
- Topical treatment of psoriasis vulgaris in adults.
- Pharmaceutical company
- LEO Pharmaceuticals
- BNF chapter
- Skin
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 September 2016